Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON long-term systemic treatment trial for adults with atopic eczema
ISRCTN11056540Phase 4Recruiting
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial of cyclosporine, methotrexate, dupilumab and abrocitinib in atopic dermatitis (AD) (4 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Primary: Eczema Area Severity Index at 6 months. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ISRCTN11056540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11056540.